PUBM vs CSTL Comparison

PubMatic is one of the leading supply-side platform providers in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, better manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). PubMatic generates revenue mainly via taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Given the growth in overall digital advertising, more publishers and advertisers are adopting programmatic (or automated) buying and selling, driving the firm's success in attracting more inventory.

Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME, among others. The company's test portfolio consists of test offerings to aid clinicians in the diagnosis and treatment of cancers or precancerous diagnoses in the fields of dermatology, gastroenterology, and ophthalmology and a pharmacogenomics ("PGx") test to guide optimal drug treatment for patients diagnosed with depression, anxiety, and other mental health conditions.